EFS of all patients as a function of level of end-consolidation MRD. Patients who were MRD⁺ (> .01%) had a significantly inferior outcome, with a 5-year EFS of 43% plus or minus 7%. This effect was seen on each of the 3 therapeutic studies (see text). Prognostic significance of end-consolidation MRD in all patients enrolled on therapeutic studies.